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Clinical findings show that male infants with hypoxic-ischemic injury (HI) fare more poorly than matched females on cognitive
outcomes. Rodent models of neonatal hypoxia-ischemia support this diﬀerence, with data showing that perinatal brain injury leads
to long-term behavioral deficits primarily in male rodents and in female rodents treated with early androgens. Results support the
idea that sex-specific gonadal hormones may modulate developmental response to injury and dovetail with overwhelming evidence
of developmental androgen eﬀects on typical brain morphology and behavior. However, mechanisms underlying sex diﬀerences
in response to early brain injury may be more complicated. Specifically, activation of cell death pathways in response to HI may
also diﬀer by sex. In females, the preferential activation of the caspase-dependent apoptotic pathway may actually aﬀord greater
protection, potentially due to the actions of X-linked inhibitor of apoptosis (XIAP) within this pathway. This contrasts the pattern
of preferential activation of the caspase-independent pathway in males. While an integrated model of sex-specific hormonal and
genetic modulation of response to early injury remains to be fully elucidated, these findings suggest that infants might benefit from
sex-specific neuroprotection following HI injury.

1. Introduction
Perinatal hypoxic-ischemic injury (HI; concurrent oxygen/blood deprivation in the brain) represents a major
cause of mortality and long-term neurologic morbidity in
premature/very low-birth-weight (VLBW) infants (<1500 g)
and in term infants suﬀering birth trauma [1]. In premature
infants, the vulnerability of the underdeveloped neural vascular system, coupled with poor cerebral autoregulation [2],
can often result in intraventricular or periventricular hemorrhagic injury (IVH-PVH; bleeding within or surrounding
the ventricles [3]). These bleeds, primarily located in the
subependymal germinal matrix, lead to some immediate cell
necrosis as well as a progressive apoptotic cell death cascade
of germinal matrix and glial precursor cells [3]. In addition,
poor cerebral autoregulation (including reperfusion failure)
in preterm infants can lead to periventricular leukomalacia
(PVL), a nonhemorrhagic ischemic injury associated with

loss of white matter surrounding the ventricles [4]. Moreover, underdevelopment of the lungs can lead to reduced
oxygenation of the blood, thus resulting in hypoxic conditions within the brain of premature infants. Animal models
of acute preterm HI injury include the Rice-Vannucci model
of unilateral carotid artery ligation followed by a period
of exposure to 8% oxygen prior to postnatal day 7 (P7),
typically performed in rodents [5–7]. Additional models
are also used in which fetal blood supply is diminished by
clamping of the placental blood supply [8, 9], and/or by
raising dams in a low-oxygen environment for a period of
days [10, 11].
In term infants, HI injury typically results from complications of birth (e.g., cord compression, placental disruption/failure, or cord asphyxia [1, 7, 12–14]) and can
result in cerebral white matter injury typical of cerebral
palsy [15] or in gray matter injury [1, 16, 17]. Thus,
term-born children experiencing asphyxia exhibit injuries
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more typical of hypoxic-ischemic encephalopathy (HIE), in
contrast to injuries exhibited by preterm children (i.e., IVHPVH, PVL). Animal models of term injury include the RiceVannucci method performed on P7-P10 [5–7] or methods
of middle cerebral artery occlusion (MCAO, [18]). Although
the mechanisms of neural damage in preterm versus term
populations diﬀer, these varied forms of injury result in
similar activation of acute necrotic and delayed apoptotic
cell death mechanisms that impact on cell populations most
vulnerable during the time of injury [5–7].
Not surprisingly, the long-term consequences of neonatal
HI injury in both populations can be severe. Nearly 50%
of term-born infants suﬀering severe HIE die within weeks
of birth, while up to 25% of those surviving exhibit
permanent neuropsychological dysfunction [7]. Similarly, a
50% mortality rate exists for preterm infants experiencing
severe HI, with 80% of survivors experiencing long-term
complications [19], including reductions in cerebellar [20],
cortical, and hippocampal volumes [21] associated in turn
with cognitive and behavioral deficits, deficits in verbal
and language domains [22, 23], reduced IQ measures
[24], cerebral palsy, and mental retardation [25]. What is
surprising, however, is the disproportionate incidence of, and
increased severity of eﬀects following, neonatal HI injury in
males. Not only are male infants more vulnerable to perinatal
insult (showing higher incidence of IVH and increased rates
of mortality from prematurity or stillbirth), they also suﬀer
more long-term cognitive deficits as compared to females
with comparable injury [23, 25–31]. In fact, males in general
show increased risk for brain-based developmental disorders,
including speech and language disorders, stutter, dyslexia,
autism, learning disabilities, attention-deficit-hyperactivity
disorder, and cerebral palsy as compared to females [26,
27, 30, 32]. Importantly, males suﬀering intracranial bleeds
at birth also display significantly lower full-scale, verbal,
and performance IQ at early school age as compared to
females matched for degree of prematurity and severity
of intracranial bleed [33]. Overall, evidence suggests that
among infants at risk for HI, females may be at a quite
significant advantage as compared to their male counterparts
who are two times more likely to experience prenatal anoxia,
hemorrhage, and infection, and 1.8 times more likely to
suﬀer cerebral birth trauma [26–28, 30].
Despite the overwhelming evidence of sex diﬀerences
in outcome following neonatal HI injury, many researchers
appear to remain naı̈ve to the importance of sex in perinatal
injury models and continue to utilize only male animals
in research studies. However, recent work concerning hormones present during the perinatal period, as well as sex
diﬀerences in mechanisms of cell death, have begun to
illustrate dynamic and diﬀering processes occurring in the
neonatal brain following injury and emphasize the need
for studies to include both sexes. This work suggests, first,
that the substantially elevated level of testosterone present in
human male fetuses during gestation through the first year of
life [34–36] may enhance neuronal excitotoxicity following
hypoxic-ischemic insult [37, 38] and may contribute to
exacerbated deficits in males [39, 40]. Second, evidence
suggests that following such injury, male and female cells
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diverge in the proportional activation of caspase-dependent
and caspase-independent pathways leading to apoptotic
death [41–43]. In fact, this diﬀerence may contribute to
outcomes that show males to be more vulnerable to early
brain damage [44–46]. Finally, data indicate that females
may possess a gene-linked advantage through a family of
inhibitors of apoptosis (IAPs [47]), the most potent being Xlinked IAP (XIAP [48]). XIAP is known to act on the caspasedependent apoptotic pathway [48–51], and it is possible that
increased expression of XIAP [52] in females may contribute
to a female advantage following neonatal HI. Taken together,
this evidence suggests an interplay of hormonal modulation
and genetically determined apoptotic mechanisms, through
which perinatal females may be aﬀorded a level of protection
against HI injury that is greater than for perinatal males.
The current paper will focus on factors that may play key
roles in the outcome of hypoxic-ischemic events experienced
by males and females, including perinatal exposure to sexspecific gonadal hormones and sex-specific cell death mechanisms. Research in this area could lead to the discovery and
clinical implementation of sex-specific neuroprotectants for
infants suﬀering from HI injury.

2. Early Hormonal Factors
Sex diﬀerences in androgen levels represent one principal
diﬀerence in the male versus female neonatal brain and lead
to substantial eﬀects on brain morphology and subsequent
behavior [34–36, 53–59]. Human testes develop around
gestational week (GW) 6, with testosterone from the testes—
as well as from the fetal adrenals (as a by-product of
corticosteroid production)—circulating at detectable plasma
levels in males by GW 8 [34, 35]. Testosterone secretion,
however, is highest from GW 10 to 20, falling to lower
levels by GW 24, followed by a second transient testosterone
surge on the day of birth (in response to the drop in
placental estrogen). In humans, testosterone levels gradually
increase during the first week of life and remain high for
the first year, peaking during the 3rd-4th month at levels
similar to the second stage of puberty (200–300 ng/dL; [35]).
Through aromatization, testosterone can be converted to 17B estradiol, thus allowing it to bind to estrogen receptors
within the brain [53, 54, 60]. In fetal male rats, where plasma
testosterone is significantly higher than female littermates
beginning at embryonic day 18 (E18) through P5 [61], the
conversion of circulating testosterone to estradiol results
in neural and behavioral masculinizing eﬀects [36, 53].
However, no studies of which we are aware directly support
this mechanism in humans. Diﬃculties in ascertaining the
role of aromatization in human sexual diﬀerentiation reflect
experimental constraints [53], but some evidence does
support a role for aromatization in human development
[62].
Human female fetuses are also exposed to androgens
from the fetal adrenal glands, as well as the maternal adrenals,
ovaries, and fat—though the amount is insuﬃcient for
masculinization. In humans, it is believed that a negative
feedback loop between the fetal adrenal cortex and the
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anterior pituitary corticotrophins minimizes female adrenal
androgen secretion, acting as a transient mechanism that
safeguards early human female development from virilization [63]. The fetal ovaries also develop at approximately
GW 7, though no circulatory estrogen of fetal ovarian
origin is present until very late in gestation [34, 35].
Likewise, studies of ovarian secretion of estrogen in the rat
reveal detectable levels 5 days after birth (corresponding
to the late third trimester human; [56]), although some
central steroidogenesis may occur [64]. In rodents, females
circumvent masculine development via maternal estrogen
(consistent with masculinization via intracellular conversion
of androgens as discussed above) through alpha-fetoprotein,
a binding globulin found in late-gestation fetuses. This
protein binds to estrogen within the bloodstream thereby
rendering it inactive and preventing virilization of the female
rodent brain [36, 54].
2.1. Testosterone and Brain Injury. As noted above, the
presence of testosterone during development represents one
of the foremost diﬀerences between neonatal male and
female brains. However, despite a large and dynamic literature concerning modulatory eﬀects of gonadal hormones
on pathologic and behavioral response to stroke injury in
adults, research data concerning hormonal modulation of
injury in neonates remains scant (but see [65]). A brief
review of this adult literature illustrates that studies using an
induced injury model simulating adult stroke—middle cerebral artery occlusion (MCAO)—show consistent evidence
that males benefit after injury from acute testosterone depletion, while the presence of testosterone increases glutamate
toxicity following injury [37]. Furthermore, testosterone and
its metabolite dihydrotestosterone (DHT) have been shown
to increase stroke damage in young adult rats [37, 66, 67],
while testosterone concentration was found to be inversely
associated with stroke severity and 6-month mortality [68,
69]. Interestingly, young male rats were also found to
incur larger strokes than their older counterparts, an eﬀect
hypothesized to be due to the ability of testosterone to
alter the susceptibility of the brain to ischemic damage in
an age-dependent manner. Alternately, though aromatase
levels are stable over age (and thus the protection aﬀorded
to aged males is not likely due to increased capability for
aromatization of testosterone to estrogen [70]), the declining
eﬀects of stroke damage in older males may reflect higher
levels of testosterone in young rats [70].
In neonatal animals, baseline sex diﬀerences have been
seen with an early hypoxia model [10, 71] as well as an
HI model [40, 72, 73] of brain injury—both of which have
shown that males exhibit increased brain volume loss [10, 40,
71, 74], disrupted myelination [10], and increased behavioral
deficits [40, 71–73] following injury as compared to liketreated females. As with adult injury models, there is also
some evidence that the presence of androgens can exacerbate
induced brain damage—for example, following GABA-A
mediated excitotoxicity [65]. Other studies of a rat model
of focal ischemic injury leading to developmental cortical
malformation (microgyria) found that androgenizing female
rat pups via testosterone propionate (TP) prior to and
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following induction of microgyria via focal cortical freezing
lesion on P1 led to a developmental shift in medial geniculate
nucleus (MGN) neuronal size distribution in adulthood—
similar to that seen in male microgyric rats—while vehicletreated microgyric females were found to be identical to
sham females (and showed no disruption of the MGN [39]).
With regard to the specific long-term eﬀects of testosterone
as a modulator of neonatal HI injury, we are aware of only
one study performed to date [40]. In this study, vehicletreated male and female rat pups, as well as female rat
pups that had been treated on postnatal days 1–5 (P1–5)
with superphysiologic levels of testosterone propionate (TP),
received the Rice-Vannucci HI procedure [5] on P7. Results
showed subsequent deficits in auditory processing ability in
males and TP-treated females with induced neonatal HI,
while no eﬀect of HI was found in vehicle-treated females
[40], thus demonstrating the apparent deleterious eﬀects
of androgen exposure in modulating behavioral deficits
associated with HI.
From these cumulative studies, it is evident that testosterone acts in some manner to exacerbate the response to
early hypoxic-ischemic injury in rats, though the specific
mechanism(s) of action remain to be defined. Moreover,
since an aromatizable form of testosterone propionate was
used in the above study [40], it is not possible to determine
whether these eﬀects were modulated directly by androgens
or via intracellular conversion to estrogen. Future studies
looking at neonatal HI while manipulating testosterone
receptors, estrogen receptors, and/or aromatase blockers
could potentially dissociate or clarify this issue. Nonetheless,
further research in the area of neonatal testosterone exposure
may help to better characterize the protection aﬀorded
to females, which potentially could be adapted to males
through some form of neuroprotective treatment. Although
the generalized use of androgen-blocking manipulations in
male infants would be a clinically untenable intervention, a
viable option could be to identify the delineated mechanisms
of androgenic exacerbation of injury and block those specific
eﬀects only.
2.2. Estrogen and Brain Injury. It must also be noted that
evidence from animal models of adult stroke shows substantial beneficial and protective eﬀects of estrogen modulation
[75–77]. In fact, adult female animals have a lower incidence
of naturally occurring stroke [78] and show less sensitivity
than male animals to the damaging eﬀects of focal or
global ischemic injury [79], and—in strains displaying
conditions known to be stroke risk factors in humans (i.e.,
hypertension)—female animals display less tissue damage
than males following induced stroke [80]. This female
advantage has been attributed at least in part to protective
eﬀects of ovarian steroid hormones, since interventions
that reduce estrogens (i.e., ovariectomy, estrogen receptor
blockade, and natural aging) have all reduced diﬀerences
in stroke outcome between the sexes [75]. Further, induced
stroke during metestrus (when estrogen is lowest) increases
tissue damage in comparison to strokes occurring during
proestrus (when estrogen is highest; [77]). It should be
noted that the eﬀects of estrogen on adult human stroke
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are less clear, and many of the successful studies of estrogen
replacement in animal models have failed to translate to
human clinical populations [75, 76]. Nonetheless, whatever
the protective mechanism(s) of estrogen may be, they are less
likely to fully account for the neonatal eﬀects described here,
since female protection has been shown in animal models
of neonatal brain injury, when minimal circulating estrogen
from the quiescent neonatal ovaries is present [40, 68, 72, 73,
81, 82] although central steroidogenesis may occur [64]. Still,
it is certainly possible that some late developmental beneficial
eﬀects of ovarian estrogen on neural reorganization after
injury could occur.
These hormonal data, taken together, suggest that early
androgen exposure in males may be a primary contributor
to the modulation of sex diﬀerences in response to HI injury
(although whether these eﬀects occur through aromatization
cannot be determined, based on data collected to date). However, another promising line of research aimed at exploring
sex diﬀerences in response to brain injury has begun to
examine possible sex diﬀerences in the mechanisms of cell
death following injury. These findings have led researchers to
believe that hormonal diﬀerences are not the only key factor
modulating sex diﬀerences in response to injury, and that the
apoptotic cascade may be diﬀerentially activated in the male
and female brain following HI.

3. The Apoptotic Cascade
Apoptosis, or programmed cell death, can be triggered by
various events including DNA damage, cytotoxic drugs, a
lack of survival signals, and developmental death signals—
among a variety of other mechanisms [83]. With regard to
neuronal death in response to hypoxia-ischemia, events are
initially triggered by a deprivation of oxygen and glucose
supply to the cell(s), which depresses both adenosine triphosphate (ATP) synthesis as well as the cellular uptake of glutamate. The accumulation of excess extracellular glutamate
triggers an increase in glutamate receptor (NMDA, AMPA,
and kainate) activation and prolonged depolarization, leading to increased calcium and sodium influx. Sodium influx
through AMPA and kainate receptors leads to cell swelling
and rapid necrotic cell death, while calcium influx through
NMDA and AMPA receptors lacking the GluR2 subunit
(rendering the channel open to calcium) activates neuronal
nitric oxide synthase (nNos). nNos, in turn, leads to the
production of the free radicals, nitric oxide (NO), and
peroxynitrate (ONOO). In caspase-independent-mediated
cell death, a reduction of nicotinamide adenine dinucleotide
(NAD+ , a high energy molecule) is caused by activation
of poly(ADP-ribose) polymerase-1 (Parp-1, a DNA repair
enzyme), leading to release of apoptosis-inducing factor
(AIF) and endonuclease G from the mitochondria to the
nucleus of the cell, and ultimately cell death [49–51].
Through a second caspase-dependent pathway, the increase
in nNos ultimately leads to mitochondrial dysfunction and
the translocation of cytochrome-c from the mitochondria to
the nucleus, signaling apoptotic protease-activating factor1 (APAF-1) and the formation of the apoptosome. The
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Figure 1: A diagram of the progression of caspase-independent and
-dependent apoptotic mechanisms.

apoptosome binds with caspase-9 (the initiator caspase),
which in turn cleaves downstream caspases 3, 6, and 7
(eﬀector caspases) causing chromatin condensation, DNA
fragmentation, and ultimately cell death [42, 50, 83–85], (see
Figure 1).
Interestingly, research has revealed the sexes to diﬀerentially favor one of these two pathways (though not exclusively), with females relying more heavily on the caspasedependent pathway and males largely utilizing the caspaseindependent pathway of cell death following HI insult. These
data derive from injury models in both adult stroke (MCAO)
and neonatal HI models [41–46, 80, 86, 87].
3.1. Apoptotic Cascades and Brain Injury. In adult stroke
models, male and female Parp-1-deficient mice both display
a reduction in Parp-1 and AIF production, suggesting the
activation of the caspase-independent apoptotic pathway by
both sexes. However, only male Parp-1-deficient animals
exhibited a reduction in stroke-induced brain damage following MCAO [86]. Likewise, female (but not male) mice
were largely resistant to endotoxin-induced mortality, and
Parp-1 inhibition decreased endotoxin-induced vascular and
inflammatory response in male (but not female) mice [88].
Interestingly, ovariectomy partially reversed the protection
normally seen in females, suggesting a modulating role of
estrogen [88]. Similarly, inhibition of Parp-1 and nNOS
was found to protect male animals from the damaging
eﬀects of MCAO (but not females, [89]). In fact, Parp-1
inhibition increased stroke damage in intact females and
estrogen-replaced ovariectomized females, again suggesting
a mediating role of estrogen [89]. Though the results of these
two studies suggest that ovarian hormones may play a role in
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modulating caspase-independent cell death in adult models,
it is important to note that sex diﬀerences in neonatal HI
are found when minimal circulating estrogen is present
(though evidence indicates central steroidogenesis may be
occurring [64]). These neonatal studies also report evidence
of predominant male use of the caspase-independent pathway, suggesting such sex diﬀerences may not be exclusively
mediated by exogenous hormones (see below). Likewise,
preferential activation of the caspase-dependent apoptotic
pathway has been seen in adult female animals following
MCAO, as increased cytochrome-c release and caspase3 cleavage was found relative to males, while inhibition
of caspase activation was found to be neuroprotective in
female animals only. This benefit was extended to ovariectomized and estrogen-replaced female animals, indicating
these eﬀects to be independent of hormones [80].
Recent work exploring cell death mechanisms in neonatal models also indicates sex diﬀerences in the preferred
apoptotic pathway following early HI [41, 42]. With regard
to the caspase-independent apoptotic pathway, both Parp1 and AIF have been found in higher concentration in the
brains of male mice following P9 HI injury, as compared to
the brains of HI-injured females [43]. Likewise, significant
protection from P7 HI injury has been shown in Parp-1
knockout male mice, though no comparable protection was
seen in females [44]. Other studies report that cytochromec and various caspases—which are active in the caspasedependent pathway—have been found in higher concentration in female as compared to male mice following P9
HI injury [43]. Likewise, inhibition of caspase cleavage has
been shown to be neuroprotective in female (but not male)
animals following P3 or P7 HI [45, 46], where translocation
of cytochrome-c was prevented. Finally, neuronal cultures
(absent of circulating hormones) subjected to cytotoxic
challenge showed diﬀering pathways of cell death—with XY
neurons predominantly utilizing the AIF-mediated caspaseindependent apoptotic pathway and XX neurons activating
the cytochrome-c, caspase-dependent apoptotic pathway
[38]. It should be noted that no studies (of which we are
aware) have quantified the exact proportional activation of
caspase-dependent and -independent apoptosis for either
sex, but instead have measured the activation of elements
specific to each pathway or the relative protection aﬀorded
to one sex over the other following knockout/inhibition of
elements specific to one pathway as stated above. These sex
diﬀerences are found to be significant in magnitude.
From these studies, it is evident that male and female
neurons undergoing apoptosis capitalize on pathways that
show sex diﬀerences unlikely to be exclusively related to
hormones (though these apoptotic pathways are not exclusive to sex). However, detailed assessment of the potential
interaction between the early (or concurrent) presence of
gonadal hormones, and the activation of sex-specific apoptotic cascades, remains to be defined. Nonetheless, apoptosis
is a major contributor to neuronal cell death and tissue loss
following neonatal HI, and the development of neuroprotectants aimed at targeting the mechanisms most utilized
by each sex represents a valuable venue of investigation for
therapeutic interventions.
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4. A Gene-Linked Female Advantage
An alternative or additional explanation for sex diﬀerences
seen in neonatal HI outcome involves endogenous inhibitors
of apoptosis. During development, the apoptotic cascade is
a highly regulated process critical for healthy development
and maintenance of tissue. This process of programmed
cell death is counterbalanced by antiapoptotic signals that
promote the survival of cells. A family of proteins, known
as inhibitors of apoptosis (IAPs), serve as endogenous
inhibitors of cell death [47, 90] and have been found
to regulate apoptosis by blocking both the intrinsic and
extrinsic mechanisms. Specifically, IAPs directly bind to
and inhibit initiator and eﬀector caspases [47, 49, 51]. The
function of IAPs has recently been extended beyond its initial
role in development and is now thought to play a role in
processes such as cancer, tumor formation, autoimmune
diseases, neurodegenerative disorders, and most recently, cell
death following brain injury [51, 91].
Of the known IAPs, X-linked IAP (XIAP) is recognized
to be the most potent [48]. XIAP eﬀectively binds to the
initiator caspase (caspase-9) and halts further cleavage of
downstream caspases (caspases 3 and 7), thus preventing
cell death [48–51]. XIAP has also been shown to bind
and inhibit caspases 3 and 7 directly [48], and in vitro
studies have revealed XIAP to severely inhibit nuclear
destruction and cytochrome-c-induced caspase activation
[48]. XIAP expression has been confirmed in both rodent
and human brains following ischemic injury [92]. Moreover,
it is understood that genetic balancing in females occurs
via random inactivation of the second X chromosome;
however, 15% of genes located on the second X chromosome
always escape inactivation, and an additional 10% sometimes
escape inactivation [52]. Therefore, it is possible that females
present with an increased expression of XIAP relative to
males. And since XIAP acts specifically on the caspasedependent pathway of cell death preferentially activated in
females, XIAP may play a role in the selective protection
aﬀorded to females following early HI injury.

4.1. X-Linked IAPs and Brain Injury. Currently very little is
known about the regulation of IAPs and XIAP in neonatal
HI injury, though surprisingly, results from studies of XIAP
knockout [93] and overexpression [94] have largely failed to
report sex diﬀerences in degree of tissue damage following
early HI injury. Further investigation revealed that these
results may be due to compensatory changes in other IAP
family members (i.e., upregulation of c-IAP1 and c-IAP2 [95,
96]), with XIAP remaining a probable source of protection
for females. One specific study examined the long-term
behavioral eﬀects of neonatal HI following inhibition of
XIAP in male and female rats [73]. Based on cumulative
evidence of sex diﬀerences in apoptotic mechanisms, coupled
with evidence of potential female protection via XIAP, this
study utilized embelin—a small molecule inhibitor of XIAP.
Embelin binds to the BIR3 domain (the biding site of
caspase-9) on the XIAP protein molecule [91], thus preventing endogenous inhibition of apoptosis by XIAP. Treatment
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with embelin increased neuropathological damage and lifelong behavioral deficits in HI females relative to vehicletreated HI females, while no comparable eﬀects were seen in
males [73]. Thus, results demonstrate both the reliance on
specific pathways of cell death between the sexes, as well as
the importance of XIAP in the protection aﬀorded to females
following injury.
Clearly more research is needed on the role of IAPs in
hypoxic-ischemic neuronal death, but the studies presented
here emphasize the need for an improved understanding
of innate mechanisms of protection in male and female
neonates. Future studies will be needed to assess the potential
interaction of hormonal exposure and genetic diﬀerences in
sex chromosome gene expression within brain cells, since sex
diﬀerences in response to early injury are almost certainly
influenced by a combination of these factors.
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for therapeutic intervention in neonates suﬀering HI brain
injury. Further, studies looking at neonatal HI while manipulating testosterone receptors, estrogen receptors, and/or
aromatase blockers could potentially dissociate or clarify the
mechanism of action promoting injury. Moreover, it seems
plausible that a lack of exposure to placental hormones
due to premature birth could also be detrimental to the
neurological development of premature infants (though no
studies, of which we are aware, have determined such eﬀects).
Given the tremendous amount of research focusing on sex
diﬀerences in adult stroke, we suggest that future research
should similarly focus on sex diﬀerences in the consequences
of neonatal HI. In fact, research in this area could yield
beneficial sex-specific neuroprotectants, with far reaching
implications for improved clinical practice and treatment.
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